Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

Novo Nordisk (NVO) executive Camilla Sylvest is departing the drugmaker after 28 years, Bloomberg’s Sara Sjolin reports. Sylvest has served as ...

This brief covers significant developments in health, including FTC's hold on an insulin lawsuit, Hungary's outbreak control ...

Bagsværd: Novo Nordisk HA has announced that Camilla Sylvest has decided to leave the company after a distinguished career of ...

Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an ...

Camilla Sylvest’s caution is possibly to be expected from an executive of a company that, until mid-2022, was known only for its critical but unspectacular business as a maker of insulin and ...

Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with ...

As China embarks on its three-year "weight management" campaign, Novo Nordisk has stepped forward with its powerful tools to ...

Effective 3 April 2025, Novo Nordisk will undergo key changes in its Executive Management. Camilla Sylvest, a long-time leader with 28 years at t ...

Camilla Sylvest, Novo Nordisk's head of commercial strategy and corporate affairs, said at the company's Capital Markets Day yesterday that the company expects to meet demand for Wegovy in the US ...

Novo Nordisk (NVO) said Thursday Camilla Sylvest has decided to leave the company, after a distinguished career of 28 years ...